Farrukh T. Awan

Farrukh T. Awan researches treatments for blood cancers, especially chronic lymphocytic leukemia (CLL) and B-cell lymphomas, with a focus on new drugs (such as BTK inhibitors and bispecific antibodies) and cell-based therapies like CAR-T and CAR-NK cells. Much of the work involves clinical trials evaluating the safety, effectiveness, and side effects (such as cytokine release syndrome and infections) of these treatments, as well as stem cell transplantation approaches for leukemia, lymphoma, and multiple myeloma.

Publication output has grown substantially over the last decade, rising from about 16 papers per year in 2017 to a peak of 67 in 2023, with continued high output (around 31-41 papers/year) through 2024-2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026